Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.80 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.74 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | THPO | P40225 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20705944 | 1.00 | SLC29A1 (0.80) | SLC29A1ADORA1ADORA3ADORA2ATSHR | |
| SCHEMBL10886676 | 0.96 | SLC29A1 (0.80) | SLC29A1ADORA1ADORA3ADORA2ATSHR | |
| SCHEMBL5675424 | 0.96 | SLC29A1 (0.80) | SLC29A1ADORA1ADORA3ADORA2ATSHR | |
| SCHEMBL5675415 | 0.96 | SLC29A1 (0.80) | SLC29A1ADORA1ADORA3ADORA2ATSHR | |
| SCHEMBL7183072 | 0.93 | SLC29A1 (0.88) | SLC29A1ADORA1ADORA3ADORA2ATSHR | |
| SCHEMBL8180763 | 0.93 | SLC29A1 (0.88) | SLC29A1ADORA1ADORA3ADORA2ATSHR | |
| SCHEMBL6762621 | 0.92 | SLC29A1 (0.83) | SLC29A1ADORA1ADORA3ADORA2ATSHR | |
| SCHEMBL20579790 | 0.91 | SLC29A1 (0.85) | SLC29A1ADORA1ADORA3ADORA2ATSHR | |
| SCHEMBL17470300 | 0.89 | SLC29A1 (0.79) | SLC29A1ADORA1ADORA3ADORA2ATSHR | |
| SCHEMBL20579787 | 0.89 | SLC29A1 (0.79) | SLC29A1ADORA1ADORA3ADORA2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11684676-B2 | Site-specific antibody-drug conjugates by ADP-ribosyl cyclases | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230128344-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES BY ADP-RIBOSYL CYCLASES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11684676-B2 | Site-specific antibody-drug conjugates by ADP-ribosyl cyclases | CD38, SARM1, NT5C2 | SLC29A1 361/4885ADORA1 685/4885ADORA3 607/4885 |
| US-20230128344-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES BY ADP-RIBOSYL CYCLASES | CD38, SARM1, NT5C2 | SLC29A1 361/4885ADORA1 685/4885ADORA3 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.